788 related articles for article (PubMed ID: 23852452)
1. In situ sequencing for RNA analysis in preserved tissue and cells.
Ke R; Mignardi M; Pacureanu A; Svedlund J; Botling J; Wählby C; Nilsson M
Nat Methods; 2013 Sep; 10(9):857-60. PubMed ID: 23852452
[TBL] [Abstract][Full Text] [Related]
2. Outlier kinase expression by RNA sequencing as targets for precision therapy.
Kothari V; Wei I; Shankar S; Kalyana-Sundaram S; Wang L; Ma LW; Vats P; Grasso CS; Robinson DR; Wu YM; Cao X; Simeone DM; Chinnaiyan AM; Kumar-Sinha C
Cancer Discov; 2013 Mar; 3(3):280-93. PubMed ID: 23384775
[TBL] [Abstract][Full Text] [Related]
3. Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing.
Bauer MA; Chavan SS; Peterson EA; Heuck CJ; Johann DJ
BMC Bioinformatics; 2014; 15 Suppl 11(Suppl 11):S3. PubMed ID: 25350881
[TBL] [Abstract][Full Text] [Related]
4. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.
Oliveras-Ferraros C; Massaguer Vall-Llovera A; Carrion Salip D; Vazquez-Martin A; Cufí S; Queralt B; Martin-Castillo B; Brunet J; de Llorens R; Menendez JA
Invest New Drugs; 2012 Apr; 30(2):846-52. PubMed ID: 21161326
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.
King CR; Swain SM; Porter L; Steinberg SM; Lippman ME; Gelmann EP
Cancer Res; 1989 Aug; 49(15):4185-91. PubMed ID: 2568168
[TBL] [Abstract][Full Text] [Related]
8. Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines.
Goecks J; El-Rayes BF; Maithel SK; Khoury HJ; Taylor J; Rossi MR
Cancer Med; 2015 Mar; 4(3):392-403. PubMed ID: 25594743
[TBL] [Abstract][Full Text] [Related]
9. [Standardization of evaluation for target molecule in cancer therapy].
Ochiai A
Gan To Kagaku Ryoho; 2011 May; 38(5):709-14. PubMed ID: 21566428
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
[TBL] [Abstract][Full Text] [Related]
11. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
12. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.
Gonzaga IM; Soares-Lima SC; de Santos PT; Blanco TC; de Reis BS; Quintella DC; de Oliveira IM; de Faria PA; Kruel CD; Andreollo NA; de Simão TA; Pinto LF
BMC Cancer; 2012 Dec; 12():569. PubMed ID: 23207070
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
[TBL] [Abstract][Full Text] [Related]
14. Highly multiplexed subcellular RNA sequencing in situ.
Lee JH; Daugharthy ER; Scheiman J; Kalhor R; Yang JL; Ferrante TC; Terry R; Jeanty SS; Li C; Amamoto R; Peters DT; Turczyk BM; Marblestone AH; Inverso SA; Bernard A; Mali P; Rios X; Aach J; Church GM
Science; 2014 Mar; 343(6177):1360-3. PubMed ID: 24578530
[TBL] [Abstract][Full Text] [Related]
15. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
16. Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells.
Mincione G; Piccirelli A; Lazzereschi D; Salomon DS; Colletta G
J Cell Physiol; 1998 Aug; 176(2):383-91. PubMed ID: 9648926
[TBL] [Abstract][Full Text] [Related]
17. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
Jiang X; Liu Y; Chen C; Zhan Z; Yan Q; Guo Y; Wang Q; Li K
Clin Lung Cancer; 2012 Jul; 13(4):288-96. PubMed ID: 22169481
[TBL] [Abstract][Full Text] [Related]
18. EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells.
Stella GM; Scabini R; Inghilleri S; Cemmi F; Corso S; Pozzi E; Morbini P; Valentini A; Dore R; Ferrari S; Luisetti M; Zorzetto M
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1327-35. PubMed ID: 23644698
[TBL] [Abstract][Full Text] [Related]
19. The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses.
Boissière-Michot F; Denouël A; Boulle N; Guillaume C; Orsetti B; Lopez-Crapez E; Chateau MC; Bibeau F
Pathol Oncol Res; 2013 Jan; 19(1):41-53. PubMed ID: 22893391
[TBL] [Abstract][Full Text] [Related]
20. [Detection of KRAS mutations: evolution or revolution for the pathologists?].
Bibeau F; Penault-Llorca F; Sabourin JC
Ann Pathol; 2008 Sep; 28(4):261-2. PubMed ID: 18928862
[No Abstract] [Full Text] [Related]
[Next] [New Search]
